


Please renumber previous pages 47-57 to now read 49-59.

In the claims:

Please cancel claims 1, 2, 12-15 and 18-24.

Please add new claims 40-52.

99
40. (NEW) A compound having the formula:



wherein:

each R1 and R2, independently, is H, C1-C12 alkyl, C6-C18 aryl, C1-C18 acyl, C7-C18 aralkyl, C7-C18 alkaryl or a dihydrotrigonellinate group;

A1 is a D or L-amino acid selected from the group consisting of Cys, Leu, Dap, Trp, Gln, a tethered amino acid with an indole ring, Phe, Hyp, any Trp derivative; CaMe-Trp, CaMe-Gln, Des-amino-Trp, Pyr, Bth, Nal, Tcc, Asn, Nva, Abu, Tyr, Tic-OH, Phe, Tip, and Dip;

A2 is a D or L-amino acid selected from the group consisting of Cys, Trp, Arg, N-Me-Arg, C α Me-Arg, Orn, Cit, hArg(R)₂, where R is selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, or alkylaryl, Lys-e-NH-R, where R is selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, or alkylaryl;

A3 is a D or L-amino acid selected from the group consisting of Glu, N-Me-Tyr,

$C_{\alpha}Me$ -Tyr, Tic-OH, Tic, Dip, Trp, Phe, des-carboxylic-Tyr (tyramine), and Tyr-(R),
where R is hydrogen or a lipophilic group;
W is -OH, -N-R₃R₄, or OR₅, where R₃, R₄, and R₅, independently, is H, C1-
C12 alkyl, C6-C18 aryl, Cl-C12 acyl, C7-C18 aralkyl, or C7-C18 alkaryl, or a
pharmaceutically acceptable salt thereof; and
each bond between two amino acids, represented by a dash ("-"), can be either a
peptide bond or a pseudopeptide bond or a pharmaceutically acceptable salt
thereof.

41. (NEW) The compound of claim 40, wherein said compound has a formula
selected from the group consisting of N- α -Ac-Trp-Arg-Tyr-NH₂.
42. (NEW) The compound of claim 40, wherein said compound is conjugated to
a carrier selected from the group consisting of cationized albumin and polylysine.
43. (NEW) The compound of claim 40, wherein the said bond between two
amino acids or amino acid derivatives is selected from the group consisting of C(O)NH,
CH₂NH, CH₂-S, CH₂-O, CH₂-CH₂, CH₂-CO, and CH₂ CH₂.
44. (NEW) The compound of claim 43, wherein a pseudopeptide bond is
positioned between A1 and A2.

45. (NEW) The compound of claim 44, wherein a pseudopeptide bond is positioned between A2 and A3.

46. (NEW) A therapeutic composition capable of attenuating a Neuropeptide Y (NPY) mediated physiological response comprising a therapeutically effective amount of the compound of claim 40 together with a pharmaceutically acceptable carrier substance.

47. (NEW) The composition of claim 46, wherein said composition is in the form of a pill, tablet, or capsule for oral administration.

48. (NEW) The composition of claim 46, wherein said composition is in the form of a liquid for oral administration.

49. (NEW) The composition of claim 46, wherein said composition is in the form of a liquid for nasal administration as drops or spray.

50. (NEW) The composition of claim 46, wherein said composition is in the form of a liquid for intravenous, subcutaneous, parenteral, or intraperitoneal administration.